12:00 AM
Oct 27, 2008
 |  BC Week In Review  |  Company News  |  Deals

Phenomix, Forest Laboratories deal

The partners will co-develop and commercialize Phenomix's dutogliptin (formerly PHX1149) to treat Type II diabetes in North America. The dipeptidyl peptidase-4 (DPP-4) inhibitor is in...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >